Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XParTS: Capecitabine and Cisplatin for Gastric Cancer Relapsed After S-1
NCT01412294Phase 2Unknown
- Sponsor
- Epidemiological and Clinical Research Information Network
- Start
- Jul 2011
- Primary completion
- Dec 2017
- Modality
- Nanoparticles, DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, Cisplatin micelle injection (HA132) in gastric cancer (GC), sponsored by Epidemiological and Clinical Research Information Network. Status: unknown.
02
Drugs
capecitabineCisplatin micelle injection (HA132)
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT01412294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01412294.